Learn about PropThink’s New Look, New Features, and PropThink Premium

Get Your First Month of PropThink Premium Half-Off
Check out the Revamped PropThink.com
Two Products Mean the Same Impactful Content at a Lower Price-Point

We’re pleased to announce the launch of the redesigned PropThink.com. We’ve updated our look, but more importantly we’ve made it that much easier for PropThink visitors and subscribers to access all of PropThink’s new and archived content – impactful research, proprietary insights, and regular news analysis.In case you missed it, here’s our latest research report highlighting the opportunity in Cempra, Inc. (CEMP), a NASDAQ-listed developer of antibiotics specifically designed to combat the growing, global risk of drug-resistant “superbugs”. In the two weeks since our report went out to PropThink Premium members, the stock has climbed by almost 20%.

As part of our redesign and in our continuing effort to provide high quality and actionable intelligence in the small-cap healthcare space, we’ve launched a number of new features at PropThink.com. These include a proprietary Catalyst Calendar, a revamped SPA database, and some user-specific tools like a note-taking application and a reading list. We’re also finalizing work on some unique financial calculators that we’ll start to launch shortly – a simple Present Value Calculator and a Financing Risk Assessment Tool to begin. All of these components are designed to enable the individual investor with trade-defining intelligence.

Most importantly, we’ve reconfigured our product line-up and pricing, bringing a new, more affordable plan online that gives PropThink visitors all the benefits of the current PropThink Premium at a lower price point. At $99/month, PropThink Premium makes more sense than ever for the active trader or investor, and with a 50% discount on your first month of service, we expect you’ll make that premium back on just one of your first few trades. Already a PropThink Premium member? Your plan remains as Premium Plus, and you can continue to enjoy early-bird delivery on all of our hard-hitting content. With Premium Plus, be the first to know what our analysts are thinking about – and the first to profit.

Either way, you’ll still get all of our top ideas by email, so there’s no need to change your habits.Finally, we’ve added a registration process for visitors who aren’t ready to commit to our high-impact products. Free membership entitles you to our weekly Newsletter and enhanced access to some of the tools and features at PropThink.com. All it takes is a few seconds and an email address.

We discussed AcelRx (ACRX) with PropThink’s Premium subscribers at the beginning of this month, highlighting again the long-term opportunity for the medical device/drug developer and why we think readers should own the stock, on the 19th. ACRX closed Friday’s trading session up 47% from our initial purchase this month.

Of course, we’d be remiss not to mention ViroPharma (VPHM). Mr. Deryugin has been pounding the table on VPHM since late last year as he saw the company making a concerted effort to shift focus from one declining product to another orphan opportunity. On the the 11th, Shire Pharmaceuticals (SHPG) purchased VPHM for $4.2 billion dollars – a 100% return for those following PropThink’s recommendation.In addition, we outlined why we’re going long Zogenix (ZGNX) this month, which just received FDA approval for Zohydro ER as the first hydrocodone product that does not contain acetaminophen. Since our report, ZGNX is up 20%.

Finally, a big thank you (and Happy Thanksgiving!) to PropThink readers who’ve followed along since our launch in 2012. We look forward to your continued support as we close out our first full year as an influential presence in the healthcare sector.